Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine 1999 June;43(2) > The Quarterly Journal of Nuclear Medicine 1999 June;43(2):155-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

  RADIOPHARMACOLOGY 

The Quarterly Journal of Nuclear Medicine 1999 June;43(2):155-8

Copyright © 2000 EDIZIONI MINERVA MEDICA

language: English

Catabolism of neurotensins. Implications for the design of radiolabeling strategies of peptides

Schubiger P. A., Allemann-Tannahill L. Egli A., Schibli R., Alberto R., Carrel-Rémy N., Willmann M., Blauenstein P., Torwué D.*

From the Center for Radiopharmaceutical Science of the Swiss Federal Institute of Technology, Zurich Paul Scherrer Institute Villigen and University Hospital Zurich, Switzerland * Vrije Universiteit Brussel, Department of Organic Chemistry Brussel, Belgium


PDF


A ­major ­impact in diag­no­sis and treat­ment of can­cer ­with pep­tide ­based radio­phar­ma­ceu­ti­cals is expect­ed. Among oth­ers neu­ro­ten­sin is con­sid­ered to be a prom­is­ing can­di­date. However, ­most neu­ro­ten­sin ana­logues, ­which ­bind to the neu­ro­ten­sin recep­tor ­have a too ­short bio­log­i­cal ­half ­live due to catab­o­lism. Therefore, sta­bi­lized frag­ments ­have ­been pre­pared and ­labeled ­with the new­ly devel­oped [Tc(CO)3]+-moie­ty. A sin­gle his­ti­dine or a (Nα-His)-Ac ­group cou­pled to the N-ter­mi­nus of the neu­ro­ten­sin frag­ments ­were ­used as a biden­tate or a tri­den­tate ­ligand respec­tive­ly, ­which coor­di­nate the met­al car­bo­nyl effi­cient­ly. Affinity and bind­ing stud­ies of the 99mTc(I) radio­lab­eled neu­ro­ten­sin frag­ments ­revealed a behav­ior influ­enced by catab­o­lism and prop­er­ties of the met­al com­plex.

top of page